Rhythm Pharma Reports Broad Positive Clinical Data for Setmelanotide and Bivamelagon Across Multiple Rare Diseases
RYTM sits 48% above its 52-week low of $60.7 on elevated volume (2.8× avg).
Summary
Rhythm Pharmaceuticals released extensive positive clinical data for its MC4R agonists, setmelanotide and bivamelagon, across Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome, highlighting significant therapeutic potential and market expansion.
Key Events · Product Development and Regulatory · RYTM
-
Positive Prader-Willi Syndrome (PWS) Phase 2 Data
Interim six-month data for setmelanotide showed consistent BMI reductions (-3.06% mean), preservation of lean mass, and clinically meaningful improvements in hyperphagia and anxiety in patients with PWS.
-
Strong Acquired Hypothalamic Obesity (HO) Efficacy
Setmelanotide demonstrated -18.9% mean BMI reduction over 2.5 years, while oral bivamelagon achieved BMI reductions ranging from -6.7% to -16.6% at one year.
-
Favorable Bardet-Biedl Syndrome (BBS) Real-World Outcomes
Real-world data for setmelanotide in BBS patients (N=286) showed 62% of adults achieved ≥10% body weight loss and a significant reduction in obesity-related healthcare visits.
-
Expanded PWS Market Opportunity
Updated epidemiology estimates project 12,500-16,000 PWS patients in the U.S. and Europe, with 8,500-12,750 living with hyperphagia and obesity.
Analysis · RYTM · Life Sciences
Rhythm Pharmaceuticals announced a comprehensive set of positive clinical data from multiple programs, including interim Phase 2 results for setmelanotide in Prader-Willi syndrome (PWS), long-term efficacy for setmelanotide and bivamelagon in acquired hypothalamic obesity (HO), and real-world outcomes in Bardet-Biedl syndrome (BBS). The PWS data showed clinically meaningful improvements in BMI, hyperphagia, and anxiety, increasing confidence for Phase 3 development. The HO data demonstrated robust and sustained weight loss, including promising results for the oral drug bivamelagon. These updates reinforce the potential of Rhythm's MC4R agonists across several rare neuroendocrine diseases and expand the estimated market opportunity for PWS.
At the time of this filing, RYTM was trading at $89.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $60.70 to $122.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.